Armin Giese researcher
Giese, Armin 1968-
VIAF ID: 927131 (Personal)
Permalink: http://viaf.org/viaf/927131
Preferred Forms
- 100 0 _ ‡a Armin Giese ‡c researcher
- 100 1 _ ‡a Giese, Armin ‡d 1968-
4xx's: Alternate Name Forms (4)
5xx's: Related Names (5)
- 551 _ _ ‡a Göttingen ‡4 ortw ‡4 https://d-nb.info/standards/elementset/gnd#placeOfActivity
- 551 _ _ ‡a Kiel ‡4 ortg ‡4 https://d-nb.info/standards/elementset/gnd#placeOfBirth
- 510 2 _ ‡a Ludwig-Maximilians-Universität München ‡b Zentrum für Neuropathologie und Prionforschung ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a Medizinische Universitätsklinik ‡g Göttingen ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 551 _ _ ‡a München ‡4 ortw ‡4 https://d-nb.info/standards/elementset/gnd#placeOfActivity
Works
Title | Sources |
---|---|
11 C Radiolabeling of anle253b: a Putative PET Tracer for Parkinson's Disease That Binds to α-Synuclein Fibrils in vitro and Crosses the Blood-Brain Barrier | |
Adjunctive N-acetyl-L-cysteine in treatment of murine pneumococcal meningitis | |
Agent strain variation in human prion disease: insights from a molecular and pathological review of the National Institutes of Health series of experimentally transmitted disease | |
Aktivierung von LINE-1 Retrotransposons durch Hypomethylierung in humanem Glioblastomgewebe | |
AMPA-receptor-mediated excitatory synaptic transmission is enhanced by iron-induced α-synuclein oligomers. | |
Analyse der Methylierungs- und Demethylierungsregulation während der zerebralen Entwicklung durch Immunhistochemie | |
Analyses of protease resistance and aggregation state of abnormal prion protein across the spectrum of human prions | |
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease | |
Automated PrPres amplification using indirect sonication | |
Bedeutung von Umwelteinflüssen auf das murine Epigenom des Hippocampus und Cerebellums | |
CADASIL mutations enhance spontaneous multimerization of NOTCH3. | |
Cell-free formation of misfolded prion protein with authentic prion infectivity | |
Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers. | |
Characterization of truncated forms of abnormal prion protein in Creutzfeldt-Jakob disease | |
Charakterisierung eines Wirkstoffes zur Hemmung pathologischer Protein-Aggregation in einem Synucleinopathie-Mausmodell | |
Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. | |
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria | |
Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA | |
Converse modulation of toxic alpha-synuclein oligomers in living cells by N'-benzylidene-benzohydrazide derivates and ferric iron | |
Correction to: Biological tumour volumes of gliomas in early and standard 20-40 min 18F-FET PET images differ according to IDH mutation status | |
Cysteine-sparing CADASIL mutations in NOTCH3 show proaggregatory properties in vitro. | |
Design of anti- and pro-aggregation variants to assess the effects of methionine oxidation in human prion protein | |
Development and implementation of a high-throughput compound screening assay for targeting disrupted ER calcium homeostasis in Alzheimer's disease | |
Different species of alpha-synuclein oligomers induce calcium influx and seeding. | |
Differential effects of prion particle size on infectivity in vivo and in vitro | |
Diffuse leukoencephalopathy with spheroids: biopsy findings and a novel mutation. | |
Diphenylpyrazole-derived compounds increase survival time of mice after prion infection. | |
Divergent molecular effects of desmin mutations on protein assembly in myofibrillar myopathy | |
Dynamic 18F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses. | |
Effect of metal ions on de novo aggregation of full-length prion protein | |
Effects of different experimental conditions on the PrPSc core generated by protease digestion: implications for strain typing and molecular classification of CJD. | |
Einfluss dreiwertiger Metallionen auf die Entwicklung des Morbus Parkinson im transgenen Mausmodell | |
Einfluss posttranslationaler Modifikationen auf die Aggregationseigenschaften des Tau-Proteins | |
Einfluss von 5-Hydroxymethylcytosin auf die Entstehung und das Wachstum des Glioblastoms | |
Einzelmolekülbasierte Analyse des Aggregationsverhaltens von Tau-Protein und sein Verhalten in der Koaggregation mit Alpha-Synuklein | |
Elevated levels of methylmalonate and homocysteine in Parkinson's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis | |
Establishing quantitative real-time quaking-induced conversion (qRT-QuIC) for highly sensitive detection and quantification of PrPSc in prion-infected tissues. | |
Establishment of novel cell culture models of Parkinson’s disease to study formation, modulation, and toxicity of α-synuclein oligomers | |
Extracellular vesicle sorting of α-Synuclein is regulated by sumoylation | |
Generation of ferric iron links oxidative stress to α-synuclein oligomer formation | |
Generation of genuine prion infectivity by serial PMCA. | |
Histopathology and clinical course of MOG-antibody-associated encephalomyelitis | |
Identification of anti-prion compounds as efficient inhibitors of polyglutamine protein aggregation in a zebrafish model | |
Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. | |
Increased alpha-synuclein aggregation following limited cleavage by certain matrix metalloproteinases | |
Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds | |
Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. | |
K27M midline gliomas display malignant progression by imaging and histology | |
Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau | |
Limited cleavage of tau with matrix-metalloproteinase MMP-9, but not MMP-3, enhances tau oligomer formation | |
Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols. | |
Modelling Ser129 phosphorylation inhibits membrane binding of pore-forming alpha-synuclein oligomers | |
Molecular dynamics simulations indicate a possible role of parallel beta-helices in seeded aggregation of poly-Gln | |
Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients. | |
Neuronal cell death in scrapie-infected mice is due to apoptosis | |
Next-generation sequencing reveals regional differences of the α-synuclein methylation state independent of Lewy body disease | |
The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. | |
Pathogenese des Nervenzellunterganges bei transmissiblen spongiformen Enzephalopathien (Prionkrankheiten) | |
Phenotypic variability of sporadic human prion disease and its molecular basis: past, present, and future | |
Photo-induced crosslinking of prion protein oligomers and prions. | |
Piperazine derivatives inhibit PrP/PrP(res) propagation in vitro and in vivo | |
Plasminogen activator inhibitor-1 influences cerebrovascular complications and death in pneumococcal meningitis. | |
Polyphenolic compounds are novel protective agents against lipid membrane damage by α-synuclein aggregates in vitro | |
Presence of phosphodiesterase type 5 in the spinal cord and its involvement in bladder outflow obstruction related bladder overactivity | |
Prion protein as copper-binding protein at the synapse. | |
The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach | |
Quantifying prion disease penetrance using large population control cohorts | |
Reduced spiral ganglion neuronal loss by adjunctive neurotrophin-3 in experimental pneumococcal meningitis | |
A refined method for molecular typing reveals that co-occurrence of PrP(Sc) types in Creutzfeldt-Jakob disease is not the rule | |
Regional pattern of microgliosis in sporadic Creutzfeldt-Jakob disease in relation to phenotypic variants and disease progression. | |
Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial | |
Seeding and transgenic overexpression of alpha-synuclein triggers dendritic spine pathology in the neocortex | |
Single-channel electrophysiology reveals a distinct and uniform pore complex formed by α-synuclein oligomers in lipid membranes | |
Single particle analysis of manganese-induced prion protein aggregates | |
Single particle analysis of tau oligomer formation induced by metal ions and organic solvents | |
Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with α-synuclein at the single molecule level | |
Synthesis of benzamide derivatives and their evaluation as antiprion agents | |
Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets | |
Toxische Oligomere in der Pathogenese des Morbus Parkinson - Elektrophysiologische Charakterisierung der Membraninteraktion und Porenbildung von pathologischen α-Synuclein Aggregaten | |
Two different binding modes of α-synuclein to lipid vesicles depending on its aggregation state | |
Typing prion isoforms. | |
Untersuchungen zu epigenetischen Modifikationen in neuronalen und glialen Zellen bei Schizophrenie | |
An unusual case of ectopic ACTH syndrome | |
α-Internexin in the diagnosis of oligodendroglial tumors and association with 1p/19q status. |